Results 81 to 90 of about 164,371 (301)

Precision medicine in pediatric oncology [PDF]

Current Opinion in Pediatrics, 2018
Purpose of review The current review describes recent advances and unique challenges in precision medicine for pediatric cancers and highlights clinical trials assessing the clinical impact of targeted therapy matched to molecular alterations identified by tumor profiling.
Forrest, Suzanne J., Geoerger, Birgit, Janeway, Katherine A.   +2 more
openaire   +2 more sources

Cell‐cycle‐specific lesion evolution rather than inhibition of double‐strand‐break repair underpins cisplatin radiosensitization

Molecular Oncology, EarlyView.
We analyze cisplatin–DNA adducts (CDAs) and double‐strand breaks (DSBs) in a cell‐cycle‐dependent manner. We find that CDAs form similarly across all cell cycle phases. DSBs arise only in S‐phase. CDAs might not directly impair DSB repair, but S‐phase DSB lesions evolve in the presence of CDAs and disrupt repair in G2, also causing radiosensitization ...
Ye Qiu, Xixi Lin, Emil Mladenov, Veronika Mladenova, Jürgen Thomale, Ali Sak, Yao Wang, Yunxuan Deng, Eleni Gkika, Martin Stuschke, George Iliakis   +10 more
wiley   +1 more source

Bispecific antibodies: advancing precision oncology [PDF]

T cell engagers; Bispecific antibodies; ImmunotherapyActivadores de células T; Anticuerpos biespecíficos; InmunoterapiaActivadors de cèl·lules T; Anticossos biespecífics; ImmunoteràpiaBispecific antibodies (bsAbs) are engineered molecules designed to ...
Pretelli, Giulia, Desai, Jayesh, GARRALDA, Elena, M. Steiner, Thiago, Herrera, Mercedes, Siu, Lillian   +5 more
core   +1 more source

Hijacking emergency granulopoiesis: Neutrophil ontogeny and reprogramming in cancer

Molecular Oncology, EarlyView.
Neutrophils are highly plastic innate immune cells; their functions in cancer extend beyond the tumour microenvironment. This Review summarises current understanding of neutrophil maturation and heterogeneity and highlights tumour‐induced granulopoiesis as a systemic programme that expands immature, immunosuppressive neutrophils via tumour‐derived ...
Gabriela Marinescu, Yi Feng
wiley   +1 more source

Precision cardio-oncology: understanding the cardiotoxicity of cancer therapy

, 2017
Current oncologic treatments have brought a strong reduction in mortality in cancer patients. However, the cancer therapy-related cardiovascular complications, in particular chemo-therapy and radiation therapy-induced cardiotoxicities are a major cause ...
Xinqiang Han, Zhou, Yun, Yun Zhou, Liu, Wendi, Wendi Liu, Han, Xinqiang   +5 more
core   +1 more source

Additional file 1 of Delivering the precision oncology paradigm: reduced R&D costs and greater return on investment through a companion diagnostic informed precision oncology medicines approach

, 2023
Additional file 1: Table S1: Probability of success of precision and non-precisiononcology medicines. Table S2:Oncology medicines, their CDxs, and clinical indications. Table S3:Oncology medicines, their clinical trials, cost, and revenue.
Jordan Clark (344134), Elaine Stewart (14709870), Mark Lawler (2349820), Peter Keeling (16498411), Dave Smart (4218022), Declan French (9919154), Richard Sullivan (18211), Raymond H. Henderson (16498402), Markus Eckstein (8597382), Adam Idica (16498405), Sandra Redmond (16498408)   +10 more
core   +1 more source

Adaptor protein CIN85 potentiates the motility of osteosarcoma cells via the Akt/mTOR and MMP2‐COL3A1 axis

Molecular Oncology, EarlyView.
CIN85 is highly expressed in osteosarcoma, particularly in metastatic lesions. Its overexpression increases cell migration and Matrigel invasion, while silencing CIN85 suppresses these behaviors. Transcriptome analysis shows that CIN85 regulates MMP2, COL3A1, and Akt/mTOR signaling. Targeting these pathways reverses CIN85‐induced motility, highlighting
Iryna Horak, Iva Staniczková Zambo, Matěj Přikryl, Peter Múdry, Danica Zapletalová, Jarmila Navrátilová, Jiří Navrátil, Jan Šmarda, Liudmyla Drobot, Petr Beneš, Lucia Knopfová   +10 more
wiley   +1 more source

PRECISION ONCOLOGY WITH ELECTRONIC MEDICAL RECORDS

European Medical Journal Innovations, 2018
Electronic medical record (EMR)-based precision oncology is a vision that is so far limited to a few pilot and basket studies, with the goal being the design of a proper treatment for cancer patients in real time, based on the panomics knowledge of the ...
Losiana Nayak, Rajat K. De
doaj  

New regulatory thinking is needed for AI-based personalised drug and cell therapies in precision oncology

Until recently the application of artificial intelligence (AI) in precision oncology was confined to activities in drug development and had limited impact on the personalisation of therapy.
Baenke, Franziska, Kämpf, Christoph, Cotte, Fabienne, Eskenazy, Deborah, Koehl, Ulrike, Breda, Gabriele, Reiche, Kristin, Gilbert, Stephen, Köhl, Ulrike, Derraz, Bouchra, Kather, Jakob Nikolas   +10 more
core   +1 more source

Molecular tests and target therapies in oncology: recommendations from the Italian workshop

, 2021
Lay abstract The increasingly precise and extensive characterization of tumors through gene profiling allows a greater understanding of the molecular mechanisms underlying tumor growth, thus permitting better, more personalized therapeutic options.
Marchetti, Antonio, Biffoni, Mauro, Martini, Nello, Popoli, Patrizia, Normanno, Nicola, The Italian Molecular Tests and Target Therapy in Oncology Workshop, Pinto, Carmine, Marchetti, Paolo, Palmieri, Giuseppe   +8 more
core   +1 more source